[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-resistance-bacterial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-resistance-bacterial":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608395","prevalence-of-carriage-of-extended-spectrum-beta-lactamase-esbl-producing-enterobacteria-in-preterm-premature-rupture-of-membranes--a-french-multicenter-cohort-study-100608395",false,"NCT07200999","Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study","Inclusion Criteria :\n\n* Pregnant women aged over 18 years\n* Diagnosed with premature rupture of membranes before term (between 23 weeks + 0 days and 36 weeks + 6 days of gestation)\n* Managed in one of the participating maternity hospitals\n\nExclusion Criteria :\n\n* No available microbiological sample\n* Minors or women under legal guardianship (curatorship, tutelage, or judicial protection)\n* Women who refuse the use of their clinical data for research purposes at admission or within one month after receiving the information document","FEMALE","18 Years",{"count":18,"type":19},250,"ESTIMATED","OBSERVATIONAL","This study looks at how common certain antibiotic-resistant bacteria (called extended-spectrum beta-lactamase-producing Enterobacteriaceae, or E-BLSE) are in pregnant women who experience premature breaking of their water before full term. The goal is to understand how often these bacteria are found, how long they stay, and what factors increase the risk of carrying them. This information will help doctors choose the best antibiotics to protect both the mother and baby from infections during and after pregnancy. The study follows women from the time of their membrane rupture until delivery, collecting samples to track the bacteria over time.",[23,24,25,26,27,28,29],"Premature Rupture of Membranes","Enterobacteriaceae","Beta-Lactams","Drug Resistance, Bacterial","Antibiotic Prophylaxis","Pregnancy","Intrauterine Infection","NOT_YET_RECRUITING","2025-09-23",{"date":33,"type":34},"2025-10-01","ACTUAL",{"date":33,"type":19},{"date":37,"type":19},"2026-12-15",{"name":39,"class":40},"Centre Hospitalier de Saint-Denis","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":41},"100600245","comparison-of-three-interventions-for-antibiotic-resistant-bacteria-arb-decolonization-from-the-gastrointestinal-tract-100600245","NCT07094984","Comparison of Three Interventions for Antibiotic-Resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract","Multicenter, Randomized, Open-label, Three-arm Study on the Efficacy of Fecal Microbiota Transplantation vs Probiotic Therapy vs Eubiotic-gut-microbiota-boosting Diet in Order to Antibiotic-resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract of Patients Colonized With Clinically Most Significant ARBs. Looking for a Strategy to Overcome the WHO Alarm on the Antibiotic Resistance \"New Pandemic\" Threat. STOP-ARB Study","STOP-ARB3","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Documented intestinal colonization with antibiotic-resistant bacteria confirmed by at least two positive cultures (rectal swabs or, alternatively, stool cultures), with the last positive result obtained at least 28 days prior to the planned procedure;\n* Documented colonization by one or more of the following bacterial strains:\n\n  1. Carbapenem-resistant strains with confirmed resistance mechanisms, including MBL+ (NDM+, VIM+, or others), KPC+, OXA-48+, or phenotypic carbapenem resistance without identified genetic mechanism;\n  2. Multidrug-resistant Enterobacteriaceae resistant to beta-lactams and other antibiotics, especially ESBL-producing strains, including Escherichia, Enterobacter, Klebsiella spp., and\u002For P. aeruginosa, A. baumannii (commonly associated with the ESKAPE group);\n  3. Gram-positive bacteria such as Enterococcus faecalis, Enterococcus faecium, or other vancomycin-resistant enterococci (VRE), as well as Staphylococcus aureus strains resistant to methicillin (MRSA) and\u002For vancomycin;\n* Absolute neutrophil count (ANC) in peripheral blood \\>500\u002FμL within 3 days prior to FMT; In case of tandem or repeated FMTs and expected neutrophil decline, the ANC test should be repeated before each FMT if the interval exceeds 3 days.\n\nFor patients without expected neutropenia (\\\u003C500\u002FμL), the blood count remains valid for 28 days;\n\n* Estimated life expectancy of at least 12 months;\n* Ability to swallow large capsules (confirmed using a test capsule) or absence of contraindications to colonoscopy;\n* No history of anaphylactic shock due to food allergies and ability to tolerate probiotic supplementation;\n* Provision of written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Lack of consent to participate in the study or inability to establish logical contact and obtain consent from an authorized representative;\n* Absolute neutrophil count (ANC) \\\u003C 500 cells\u002FμL on the day of FMT (within 3 days prior) or predicted decline to this level within the next 2 days;\n* Diagnosed HIV infection with CD4 lymphocyte count \\\u003C 250 cells\u002FμL;\n* Active infection requiring antibiotic therapy on the day of FMT or planned antibiotic use during the first 7 days following FMT;\n* Symptoms or radiological\u002Fendoscopic evidence of gastrointestinal mucosal damage within 7 days prior to FMT (e.g., ulceration, perforation, gastrointestinal bleeding) posing a risk of serious adverse events;\n* Contraindications for FMT administration via upper or lower gastrointestinal tract routes (e.g., gastrointestinal perforation, anal atresia, lack of intestinal continuity, or other);\n* Inability to undergo preparatory therapy (oral antibiotics: colistin, vancomycin, gentamicin and\u002For bowel cleansing agents) prior to FMT;\n* Inability to swallow large capsules (confirmed with test capsules) or contraindications for colonoscopy;\n* Severe food allergy with history of anaphylactic shock or inability to tolerate probiotics;\n* Pregnancy or breastfeeding;\n* Severe medical conditions contraindicating study protocol adherence as determined by the treating physician (e.g., severe heart failure precluding bowel cleansing due to risk of fluid overload or dehydration);\n* Participation in another clinical trial and administration of an investigational drug or device within 3 months prior to randomization;\n* Reluctance or inability to comply with protocol requirements, including any physical, mental, or social condition that may impair the participant's ability to adhere to the protocol.","ALL",{"count":52,"type":19},360,"INTERVENTIONAL",[55],"NA","The aim of this research experiment is to evaluate the effectiveness of fecal microbiota transplantation (FMT) preceded by antibiotic pre-treatment versus probiotic therapy and a standard-of-care equivalent diet designed to stimulate the growth of eubiotic gut microbiota (an active comparator enhancing the ethical value of the study and increasing the chances of spontaneous decolonization of antibiotic-resistant bacteria (ARB) in the absence of any active intervention recommended by Scientific Societies) in the decolonization of bacteria with the most clinically significant antibiotic resistance mechanisms from the gastrointestinal tract of colonized patients.\n\nThis study addresses the urgent need highlighted by the World Health Organization (WHO) for new strategies to combat antibiotic resistance, aiming to prevent its progression into a global pandemic that could undermine the achievements of modern civilization.\n\nStudy Hypotheses:\n\n* The decolonization rate of ARB bacteria in patients undergoing the intervention (FMT or probiotic therapy) is the same as in patients treated with standard-of-care (SoC) alone.\n* The decolonization rate of ARB bacteria in the intervention groups (FMT or probiotic therapy) is at least 20 percentage points higher than in patients treated with the standard approach (diet).\n\nThe findings from this study may contribute to developing innovative microbiota-based therapies for the decolonization of antibiotic-resistant bacteria and help reduce the global burden of antibiotic resistance.",[26,58],"Antimicrobial Drug Resistance",[60,61,62,63,64,65],"Fecal Microbiota Transplantation","FMT","Antibiotic-resistant bacteria decolonization","Eradication procedure","probiotic therapy","eubiotic diet","RECRUITING","2025-08-26",{"date":69,"type":34},"2025-09-03",{"date":71,"type":34},"2024-12-31",{"date":73,"type":19},"2027-04-30",{"name":75,"class":40},"Medical University of Warsaw",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":50,"minAge":16,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100596986","antibiotic-treatment-for-pneumonia-caused-by-stenotrophomonas-maltophilia-in-icu-patients-100596986","NCT07052604","Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023\n* Intubated and mechanically ventilated\n* Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients who refuse the use of their data for research purposes",{"count":83,"type":19},300,"This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.",[86,87,88,89,26],"Pneumonia, Ventilator-Associated","Stenotrophomonas Maltophilia","Intensive Care Units","Anti-Bacterial Agents","2025-06-26",{"date":92,"type":34},"2025-07-04",{"date":94,"type":34},"2023-12-15",{"date":96,"type":19},"2025-09-15",{"name":39,"class":40}]